AI-powered, load-and-go platform has potential to radically shift how veterinarians process, diagnose, and act on cytology and blood morphology cases The global launch of the IDEXX (IDXX) inVue Dx ...
IDEXX Laboratories (NASDAQ:IDXX) President and CEO Michael Erickson used a Stifel investor conference appearance to emphasize the company's innovation pipeline, expanding commercial reach and growing ...
Investing.com - Leerink Partners has reiterated an Outperform rating and $580.00 price target on IDEXX Laboratories (NASDAQ:IDXX), citing the successful launch of the company’s InVue Dx diagnostic ...
IDEXX benefits from CAG diagnostics growth and innovations like Cancer Dx and inVue Dx. IDEXX reported 10% organic growth in Q4 2025 CAG Diagnostics recurring revenues on volume gains and pricing.
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. IDEXX Laboratories, Inc. is one of the best cancer stocks. TheFly reported on May 5 that IDXX saw its valuation ...
(MENAFN- PR Newswire) AI-powered, load-and-go platform has potential to radically shift how veterinarians process, diagnose, and act on cytology and blood morphology cases The global launch of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results